It's more than that though in my view. What you said is spot on...

It's more than that though in my view. What you said is spot on but there is so much more colour.

The numbers indicate just how much value is on the table for Neuren.

Based on the slide from the Acadia presentation, Retts has somewhere between 6,000-9,000 patients in the US. Let's run with the mid-point of 7,500. Google indicates that there are between 4,000 - 6,000 patients with Friedreich's Ataxia in the US, so let's run with the mid-point of 5,000.

If you look at the three conditions we are currently treating (PMS, PHS, AMS) and take the numbers published in the 2023 AR, you get 24,000, 6,000 and 19,000 respectively for a total of 49,000 patients.

The three conditions alone, without PWS, amount to 9.8 times the number of patients that have Friedreich's Ataxia.

I know it's not a simple case of saying Reata is worth $7.2b USD, so based on patient numbers, 2591 in the three conditions is worth $70.5b USD but it does provide some food for thought. It makes it all the more interesting when you consider there are still a number of other undisclosed conditions and other treatment possibilities still yet to be explored, let alone Fragile X treatments at some point.